L
Larimar Therapeutics, Inc. (LRMR)
NGM – Real Time Price. Currency in USD
3.66
+0.16 (4.57%)
At close: Jun 26, 2026, 4:00 PM EDT
4.00
+0.34 (9.29%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
3.66
+0.16 (4.57%)
At close: Jun 26, 2026, 4:00 PM EDT
4.00
+0.34 (9.29%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director |
| Dr. Gopi Shankar M.B.A., Ph.D. | Chief Development Officer |
| Dr. Russell G. Clayton Sr., D.O. | Chief Medical Officer |
| Mr. Francis Michael Conway CPA | VP & Controller |
| Mr. John Berman | Vice President of Finance & Administration |
| Mr. Michael Celano CPA | Secretary & CFO |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance |
| Date | Type | Document |
|---|---|---|
| 2026-05-19 | 8-K | lrmr-20260519.htm |
| 2026-05-14 | 8-K | lrmr-20260514.htm |
| 2026-05-14 | 10-Q | lrmr-20260331.htm |
| 2026-04-20 | DEF 14A | lrmr-20260416.htm |
| 2026-04-20 | ARS | lrmr_ars_123125.pdf |
| 2026-04-10 | PRE 14A | lrmr-20260410.htm |
| 2026-03-19 | S-8 | d122362ds8.htm |
| 2026-03-19 | 8-K | lrmr-20260319.htm |
| 2026-03-19 | 10-K | lrmr-20251231.htm |
| 2026-03-09 | 8-K | lrmr-20260309.htm |